Transfusion transmitted HIV

Vox Sanguinis

Volumn 70, Issue SUPPL. 3, 1996, Pages 1-3

  Dodd, Roger Y ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

Blood; HIV; Risk; Transfusion

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TRANSFUSION; CONFERENCE PAPER; HAITI; HEMOPHILIA; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INTRAVENOUS DRUG ABUSE; LIFE CYCLE; PRIORITY JOURNAL; RISK; UNITED STATES; VIRUS ISOLATION; VIRUS TRANSMISSION;

EID: 0029976626     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1996.tb01358.x     Document Type: Conference Paper

References (13)

1. Banerjee K, Rodrigues J, Israel Z, Kulkarni S, Thakar M: Outbeak of HIV seropositivity among commercial plasma donors in Pure, India. Lancet 1989;2:166.
2. Busch MP, Young MJ, Samson SM, et al: Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991;31:4-11.
3. Quinn TC: Epidemiologic trends in HIV infection. Curr Opin Infect Dis 1992;5:189-200.
4. Loussert-Ajaka I, Ly TD, Chaix ML, et al: HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994;343:1393-1394.
5. Schable C, Zekeng L, Pau C-P, et al: Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994;344:1333-1334.
6. Petersen LR, Satten GA, Dodd R, et al: Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994;34:283-289.
7. Busch MP, Lee LLL, Satten GA, et al: Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995;35:91-97.
8. Lackritz EM, Satten GM, Aberle-Grasse J, et al: Estimated risk of HIV transmission by screened blood in the United States. New Engl J Med 1995;333:1721-1725
9. Busch MP, Alter HJ: Will human immunodeficiency virus p24 antigen screening increase the safety of the blood supply and, if so, at what cost. Transfusion 1995;35:536-539.
10. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW: Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-831.
11. Deacon NJ, Tsykin A, Solomon A, et al: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
12. Vamvakas E, Kaplan HS: Early transfusion and length of survival in acquired immune deficiency syndrome: Experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-118.
13. Busch MP, Lee T-H, Heitman J: Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: Implications for transfusion support of infected patients. Blood 1992;80:2128-2135.